comparison of newer and higher dose antibiotics combination therapy with old and standard antibiotics combination therapy in critically ill patients who are carbapenem resistant enterobacteriaceae (CRE)

Phase 4

• Conditions: Health Condition 1: R799- Abnormal finding of blood chemistry, unspecified

• Registration Number: CTRI/2022/09/045736
• Lead Sponsor: Department of Anaesthesiology and Critical and Care Jawaharlal Nehru Medical College AMU Aligarh

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Patient having sepsis and SOFA score of 2 or more than 2 at the time of admission in icu/ccw.

2.There should be an isolates of carbapenem resistant enterobacteriaceae (CRE) positive either from Blood, tracheal aspirates, urine or abdominal pus culture.

3.Patient on any empirical antibiotics except current combination therapy .

Exclusion Criteria

1.Patient who is not having sepsis and having SOFA score of less than 2. Non Carbapenem resistant enterobacteriaceae (CRE) patients.

3.Patient who expire within 48 hours of starting the combination

therapy.

4.Patient having sensitivity to the drug use .

5.Covid -19 positive patients

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To see the changes in sequential organ failure assessment (SOFA) score at zero hour and after 48 hours of starting combination therapies meropenem plus colistin and high dose tigecycline plus colistin in carbapenem resistant enterobacteriaceae positive cases.Timepoint: 2 days

Secondary Outcome Measures

Name	Time	Method
To see the microbiological eradication of carbapenem resistant enterobacteriaceae on 5th day and to report any mortality within 5 days of starting the antibiotics combination therapies .Timepoint: 5 days